Table II. Pharmacogenetics of antidepressant drugs and candidate genes. SERT, serotonin transporter; 5-HT2a, serotonin receptor 2A; TPH1, tryptophan hydroxylase 1; Gβ3, G-protein β3 subunit; NET, norepinephrine transporter; MAO-A, monoamine oxidase A; DRD2, dopamine D2 receptor; DRD3 D3 receptor; DRD4, dopamine D4 receptor; ACE, angiotensin-converting enzyme; BDNF, brain-derived neurotrophic factor; FKBP5: FK506 binding protein 5.
| Gene | Polymorphism | Finding |
| SERT | 44 bp Ins/del | Response to SSRIs (fluoxetine, fluvoxamine, citalopram, paroxetine) |
| 5-HT2A | T102C, C-1420T, G-1438A | No association |
| TPH1 | A218C | C/C associated with better response to fluvoxamine, paroxetine |
| Gβ3 | C825T | T/T associated with better response |
| NET | T-182C; G-1287A | No association |
| MAO-A | 30 bp repeat | No association |
| DRD2 | Ser311Cys | No association |
| DRD3 | Ser9Gly | No association |
| DRD4 | 48 bp repeats | No association |
| ACE | ins/del | Discrepant results |
| BDNF | Val166Met | No association |
| FKBP5 | rs1360780 (C/T) | TT associated with better response |